BB Biotech AG (BB Biotech AG) LT-Debt-to-Total-Asset : 0.12 (As of Dec. 2023)

View and export this data going back to . Start your Free Trial

What is BB Biotech AG LT-Debt-to-Total-Asset?

LT Debt to Total Assets is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. It is calculated as a company's Long-Term Debt & Capital Lease Obligationdivide by its Total Assets. BB Biotech AG's long-term debt to total assests ratio for the quarter that ended in Dec. 2023 was 0.12.

BB Biotech AG's long-term debt to total assets ratio declined from Dec. 2022 (0.12) to Dec. 2023 (0.12). It may suggest that BB Biotech AG is progressively becoming less dependent on debt to grow their business.

BB Biotech AG LT-Debt-to-Total-Asset Historical Data

The historical data trend for BB Biotech AG's LT-Debt-to-Total-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

BB Biotech AG LT-Debt-to-Total-Asset Chart

BB Biotech AG Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

LT-Debt-to-Total-Asset

Get a 7-Day Free Trial

0.04

0.02

0.10

0.12

BB Biotech AG Quarterly Data
	Jun16	Sep16	Dec16	Mar17	Jun17	Dec17	Dec18	Dec19	Dec20	Mar21	Jun21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
LT-Debt-to-Total-Asset	Get a 7-Day Free Trial															0.12	0.12	0.12	0.12	0.12

BB Biotech AG LT-Debt-to-Total-Asset Calculation

BB Biotech AG's Long-Term Debt to Total Asset Ratio for the fiscal year that ended in Dec. 2023 is calculated as

LT Debt to Total Assets (A: Dec. 2023 )	=	Long-Term Debt & Capital Lease Obligation (A: Dec. 2023 )	/	Total Assets (A: Dec. 2023 )
	=	352.567	/	3049.438
	=	0.12

BB Biotech AG's Long-Term Debt to Total Asset Ratio for the quarter that ended in Dec. 2023 is calculated as

LT Debt to Total Assets (Q: Dec. 2023 )	=	Long-Term Debt & Capital Lease Obligation (Q: Dec. 2023 )	/	Total Assets (Q: Dec. 2023 )
	=	352.567	/	3049.438
	=	0.12

BB Biotech AG (GREY:BBAGF) LT-Debt-to-Total-Asset Explanation

LT Debt to Total Asset is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. A year-over-year decrease in this metric would suggest the company is progressively becoming less dependent on debt to grow their business.

BB Biotech AG LT-Debt-to-Total-Asset Related Terms

Thank you for viewing the detailed overview of BB Biotech AG's LT-Debt-to-Total-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.

BB Biotech AG (BB Biotech AG) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » BB Biotech AG (GREY:BBAGF) » Definitions » LT-Debt-to-Total-Asset

Comparable Companies

Traded in Other Exchanges

BIONz:UK BBZA:Germany BION:Switzerland

Address

Schwertstrasse 6, Schaffhausen, CHE, CH-8200

Website

https://www.bbbiotech.com

BB Biotech AG is a part of the healthcare sector in Switzerland. Its primary activity includes making investments, especially in the biotechnology market and is one of the largest investors in the field of biotechnology. The focus of the investments is on those listed companies that focus on the development and marketing of novel drugs with a clear value for the healthcare system. BB Biotech follows a strategy of carefully screening and selecting biotechnology firms with a long-term time horizon and having established products in the marketplace. Geographically it earns key revenue from the Netherlands.

BB Biotech AG (BB Biotech AG) Headlines

No Headlines